GSK Exceeded Expectations In 2022, Now Looking For Edge Over Pfizer In RSV Battle
Companies Will Reveal US Pricing Shortly
Having outperformed in 2022, GSK is gearing up for key regulatory and market access decisions on its RSV vaccine, but is confident it holds superior data compared with rival Pfizer.
